Biotech News

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Talphera Inc (TLPH)TalpheraEarnings

Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million ; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late

Related news

Talphera Inc

Critical-Care Therapeutics Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings. Its lead program addresses anticoagulation during continuous renal replacement therapy. Niyad Niyad is a regional citrate anticoagulant designed for use in the extracorporeal circuit during...

Recent company news

Stock data

Close
0.74 USD
Market cap
40.24M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States